Tag Archives: analyst

‘Old guard’ generics players yield U.S. lead to Indian up-and-comers: analyst

The U.S. generics world has changed. Starting from around late 2018 to early 2019, traditional generics bigwigs Teva, Mylan, Novartis’ Sandoz, Amneal and Endo have lost out to a group of six competitors that include Indian drugmakers Aurobindo Pharma, Lupin, Dr. Reddy’s, Sun Pharma, Cipla and Canada’s Apotex in terms of weekly total prescriptions, Evercore… Read More »

With safety data, Bayer could challenge Erleada, Xtandi in prostate cancer: analyst

For years, Johnson & Johnson and the Pfizer-Astellas team have been the only players in their class of prostate-cancer fighters. But Bayer is waiting in the wings, and stellar new safety data could make it a threat. The German drugmaker trumpeted phase 3 data Thursday on its androgen receptor antagonist candidate, darolutamide, showing that the drug… Read More »